Grants / Department of Defense / Defense Health Agency Contracting Activity - DHACA

HT942525PRCRPCTA: DOD Peer Reviewed Cancer, Clinical Trial Award

Closed Closed September 25, 2025 Opportunity HT942525PRCRPCTA ☆ Save

This grant is closed. A newer notice from the same program is open now: DoW Breast Cancer, Clinical Research Extension Award (HT942526BCRPCREA2). Status: Closes November 18, 2026 (11 days left). It is in our archive of Defense Health Agency Contracting Activity - DHACA notices from 2025.

• Total funding$33.6 million
• Expected awards8
• Cost sharingNot required
• Funding typeGrant

Key dates

Who can apply

This opportunity was open to any type of organization.

• Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses, individuals.

Is this a realistic fit?

• Most of the program's money (59% over five years) went to colleges and universities.
• No cost sharing or match is required.

What the grant funds

Summary: The fiscal year 2025 (FY25) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY25 PRCRP topic areas. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations. Distinctive Features: • Applications to this award mechanism must include a clinical trial. • Projects can range from phase 0 to phase III. • If an Investigational New Drug Application (IND) or an Investigational Device Exemption (IDE) is required, the application must be submitted to the FDA prior to the FY25 PRCRP Clinical Trial Award application submission deadline (this includes clinical trials requesting exception from informed consent under Code of Federal Regulations, Title 21, Part 50.24 (21 CFR 50.24). • Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date. Funding Details: (New for FY25) Funding limits are now listed as total cost limits, which is the combination of both direct and indirect costs.

Category: Science and Technology and other Research and Development.

Applying now

This notice no longer takes applications. Apply under the newer notice, HT942526BCRPCREA2, which is open now.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.